Role of macrolide antibiotics in the treatment of chronic pulmonary diseases
DOI:
https://doi.org/10.6016/ZdravVestn.2955Keywords:
macrolide antibiotics, CoPD, asthma, cystic fibrosis, bronchiectasis, exacerbationsAbstract
Chronic lung diseases are among the leading causes of morbidity and mortality. Despite adequate therapy, some patients fail to fully respond to treatment. Macrolide antibiotics are becoming one of the standard treating options in chronic pulmonary diseases, owing to their anti-inflammatory and antibiotic effects. Firstly, they minimise the adherence and mobility of the bacteria and affect biofilm formation. Secondly, they influence the expression of tight junction proteins and change the mucus composition. They increase antimicrobial susceptibility of bacteria when used in combination with other antibiotics. Beneficial effects on the quality of life and on the number of acute exacerbations in airways diseases have been described. Nonetheless, adverse effects have to be considered. Most importantly, appropriate selection of patients is necessary because long-term use of macrolide antibiotics promotes bacterial resistance in general population.
Downloads
References
1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
DOI: 10.1183/13993003.00164-2019
PMID: 30846476
2. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659-68.
DOI: 10.1016/S0140-6736(17)31281-3
PMID: 28687413
3. Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, et al. The potential impact of azithromycin in idiopathic pulmonary fibrosis. Eur Respir J. 2019;53(2):1800628.
DOI: 10.1183/13993003.00628-2018
PMID: 30442715
4. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration. 2011;81(1):67-74.
DOI: 10.1159/000320319
PMID: 20733281
5. Cirioni O, Ghiselli R, Silvestri C, Minardi D, Gabrielli E, Orlando F, et al. Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection. J Antimicrob Chemother. 2011;66(6):1318-23.
DOI: 10.1093/jac/dkr107
PMID: 21406436
6. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J. 1997;10(5):971-2.
DOI: 10.1183/09031936.97.10050971
PMID: 9163632
7. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, et al. The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial. In: PLoS One. 2014;9(8):e105609.
DOI: 10.1371/journal.pone.0105609
PMID: 25148049
8. Asgrimsson V, Gudjonsson T, Gudmundsson GH, Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother. 2006;50(5):1805-12.
DOI: 10.1128/AAC.50.5.1805-1812.2006
PMID: 16641453
9. Tojima I, Shimizu S, Ogawa T, Kouzaki H, Omura S, Sunazuka T, et al. Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium. Auris Nasus Larynx. 2015;42(4):332-6.
DOI: 10.1016/j.anl.2015.02.003
PMID: 25769240
10. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med. 2002;165(8):1113-8.
DOI: 10.1164/ajrccm.165.8.2103094
PMID: 11956054
11. Tan WC. Viruses in asthma exacerbations. Curr Opin Pulm Med. 2005;11(1):21-6.
PMID: 15591884
12. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618-23.
DOI: 10.1164/ajrccm.164.9.2105011
PMID: 11719299
13. Kobrehel G, Lazarevski G, Dokić S, Kolacny-Babić L, Kucisec-Iepes N, Cvrlje M. Synthesis and antibacterial activity of O-methylazithromycin derivatives. J Antibiot (Tokyo). 1992;45(4):527-34.
DOI: 10.7164/antibiotics.45.527
PMID: 1317368
14. Stepanić V, Žiher D, Gabelica-Marković V, Jelić D, Nunhuck S, Valko K, et al. Physicochemical profile of macrolides and their comparison with small molecules. Eur J Med Chem. 2012;47(1):462-72.
DOI: 10.1016/j.ejmech.2011.11.016
PMID: 22152985
15. Taylor SP, Sellers E, Taylor BT. Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly. Am J Med. 2015;128(12):1362.e1-6.
DOI: 10.1016/j.amjmed.2015.07.032
PMID: 26291905
16. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med. 1998;4(2):116-21.
DOI: 10.1097/00063198-199803000-00010
PMID: 9612675
17. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829-32.
DOI: 10.1164/ajrccm.157.6.9710075
PMID: 9620913
18. Castellani C, Duff AJ, Bell SC, Heijerman HG, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-78.
DOI: 10.1016/j.jcf.2018.02.006
PMID: 29506920
19. Amitani R, Wilson R, Rutman A, Read R, Ward C, Burnett D, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol. 1991;4(1):26-32.
DOI: 10.1165/ajrcmb/4.1.26
PMID: 1898852
20. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57(3):212-6.
DOI: 10.1136/thorax.57.3.212
PMID: 11867823
21. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al.; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-56.
DOI: 10.1001/jama.290.13.1749
PMID: 14519709
22. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax. 2006;61(10):895-902.
DOI: 10.1136/thx.2005.057950
PMID: 16809416
23. Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, et al.; OPTIMIZE Study Group. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med. 2018;198(9):1177-87.
DOI: 10.1164/rccm.201802-0215OC
PMID: 29890086
24. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al.; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303(17):1707-15.
DOI: 10.1001/jama.2010.563
PMID: 20442386
25. Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al.; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-9.
DOI: 10.1164/rccm.201207-1160OE
PMID: 23540878
26. Olveira C, Padilla A, Martínez-García M-Á, de la Rosa D, Girón R-M, Vendrell M, et al. Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. Arch Bronconeumol. 2017;53(7):366-74.
DOI: 10.1016/j.arbres.2016.12.003
PMID: 28118936
27. Gao YH, Guan WJ, Liu SX, Wang L, Cui JJ, Chen RC, et al. Aetiology of bronchiectasis in adults: A systematic literature review. Respirology. 2016;21(8):1376-83.
DOI: 10.1111/resp.12832
PMID: 27321896
28. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251-9.
DOI: 10.1001/jama.2013.1937
PMID: 23532241
29. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-7.
DOI: 10.1016/S0140-6736(12)60953-2
PMID: 22901887
30. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260-7.
DOI: 10.1001/jama.2013.2290
PMID: 23532242
31. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
DOI: 10.1183/13993003.00629-2017
PMID: 28889110
32. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-56.
DOI: 10.1172/JCI36130
PMID: 18982161
33. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-20.
DOI: 10.1136/thorax.55.2.114
PMID: 10639527
34. Huckle AW, Fairclough LC, Todd I. Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics. Respir Care. 2018;63(5):609-19.
DOI: 10.4187/respcare.05943
PMID: 29463692
35. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98.
DOI: 10.1056/NEJMoa1104623
PMID: 21864166
36. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361-8.
DOI: 10.1016/S2213-2600(14)70019-0
PMID: 24746000
37. Pomares X, Montón C, Bullich M, Cuevas O, Oliva JC, Gallego M, et al. Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment. Chest. 2018;153(5):1125-33.
DOI: 10.1016/j.chest.2018.01.044
PMID: 29427576
38. Naderi N, Assayag D, Mostafavi-Pour-Manshadi SM, Kaddaha Z, Joubert A, Ouellet I, et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respir Med. 2018;138:129-36.
DOI: 10.1016/j.rmed.2018.03.035
PMID: 29724384
39. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218-24.
DOI: 10.1164/rccm.200711-1754OC
PMID: 18480428
40. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353(9171):2213-4.
DOI: 10.1016/S0140-6736(99)01813-9
PMID: 10392993
41. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322-9.
DOI: 10.1136/thoraxjnl-2012-202698
PMID: 23291349
42. Global Initiative for AsthmaGlobal Strategy for Asthma Management and Prevention. [cited 2019 Aug 01]. Available from: http://www.ginaasthma.org/.
43. Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267-81.
DOI: 10.2147/JAA.S153097
PMID: 30464537
44. Gauthier JM, Hachem RR, Kreisel D. Update on Chronic Lung Allograft Dysfunction. Curr Transplant reports. 2016;3(3):185-91.
DOI: 10.1007/s40472-016-0112-y
PMID: 28090432
45. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003;168(1):121-5.
DOI: 10.1164/rccm.200212-1424BC
PMID: 12672648
46. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174(5):566-70.
DOI: 10.1164/rccm.200601-071OC
PMID: 16741151
47. Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, et al. Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. 2019;1:CD011825.
DOI: 10.1002/14651858.CD011825.pub2
PMID: 30656650
48. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90.
DOI: 10.1056/NEJMoa1003833
PMID: 22591294
49. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al.; ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352(16):1637-45.
DOI: 10.1056/NEJMoa043526
PMID: 15843666
50. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50(11):3646-50.
DOI: 10.1128/AAC.00234-06
PMID: 16940064
51. Cizman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents. 2003;21(4):297-307.
DOI: 10.1016/S0924-8579(02)00394-1
PMID: 12672574
52. Čizman M, Bajec T, Korošec A. Poraba antibiotikov v Sloveniji in drugod po svetu. Ljubljana: Slovensko zdravniško društvo, Sekcija za protimikrobno zdravljenje; 2019 [cited 2019 Aug 22]. Available from: http://www.szpz.info/content/2018/podiplomskitecaj/Milan_Cizman_Tom_Bajec_Ales_Korosec-Poraba_antibiotikov_v_sloveniji_in_drugod.pdf.
53. Paragi M, Mioč V, Kastrin T, Kraigher A, Čretnik Žohar T. Slovenska skupina za meningitise. Invazivne pnevmokokne okužbe po uvedbi cepljenja s konjugiranim cepivom v nacionalni program cepljenja. Med Razgl. 2016;55:121-31.
54. Štrumbelj I, Berce I, Čretnik-Žohar I, Harlander T, Jeverica S, Kavčič M, et al. Pregled občutljivosti bakterij za antibiotike - Slovenija 2011. 1. izd. Ljubljana: Slovenska komisija za ugotavljanje občutljivosti za protimikrobna zdravila (SKUOPZ); 2011 [cited 2019 Aug 22]. Available from: http://www.imi.si/strokovna-zdruzenja/skuopz/dokumenti/bakterijska-obcutljivost-v-sloveniji-2011.pdf.
55. Štrumbelj I, Pirš M, Berce I, Bombek Ihan M, Fišer J, Golle A, et al. Pregled občutljivosti bakterij za antibiotike - Slovenija 2017. 1. izd. Ljubljana: Slovenska komisija za ugotavljanje občutljivosti za protimikrobna zdravila (SKUOPZ); 2017 [cited 2019 Aug 22]. Available from: http://www.imi.si/strokovna-zdruzenja/skuopz/dokumenti/skoupz_porocilo_2017_CIP.pdf.
56. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection. 2001;29(5):251-6.
DOI: 10.1007/s15010-001-1072-3
PMID: 11688901
57. Taylor SL, Leong LEX, Mobegi FM, Choo JM, Wesselingh S, Yang IA, et al. Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. Am J Respir Crit Care Med. 2019;200(3):309-17.
DOI: 10.1164/rccm.201809-1739OC
PMID: 30875247
58. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007;26(1):8-12.
DOI: 10.1097/01.inf.0000247109.44249.ac
PMID: 17195698
59. Tramper-Stranders GA, van der Ent CK, Gerritsen SA, Fleer A, Kimpen JL, Wolfs TF. Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts? J Antimicrob Chemother. 2007;60(3):665-8.
DOI: 10.1093/jac/dkm235
PMID: 17604321
60. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42.
DOI: 10.1136/gutjnl-2012-302254
PMID: 22580412
61. Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2016;28(6):676-83.
DOI: 10.1097/MEG.0000000000000590
PMID: 26862930
62. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72:ii1-64.
DOI: 10.1136/thoraxjnl-2017-210927
PMID: 29054853
63. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416.
DOI: 10.1164/rccm.200604-571ST
PMID: 17277290
64. Grosset J, Ji B. Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex. Drugs. 1997;54:23-7.
DOI: 10.2165/00003495-199700542-00006
PMID: 9358197
65. Hosono Y, Kitada S, Yano Y, Mori M, Miki K, Miki M, et al. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. J Infect Chemother. 2018;24(5):353-7.
DOI: 10.1016/j.jiac.2017.12.008
PMID: 29361415
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
